Sergio Perez-Ramirez
Guadalajara, JAL 44340, Mexico
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Managing Osteoarthritis Pain in Underrepresented Populations: Insights from Mexico and Latin America.
Journal: Journal of clinical medicine
Published: January 23, 2026
The distinct transcriptomic signature of the resolution phase fibroblast-like synoviocytes supports endothelial cell dysfunction.
Journal: Communications biology
Published: May 13, 2024
Complementary and Alternative Medicine (CAM) Practices: A Narrative Review Elucidating the Impact on Healthcare Systems, Mechanisms and Paediatric Applications.
Journal: Healthcare (Basel, Switzerland)
Published: May 02, 2024
MyD88 dimerization inhibitor ST2825 targets the aggressiveness of synovial fibroblasts in rheumatoid arthritis patients.
Journal: Arthritis research & therapy
Published: November 18, 2022
Targeting MyD88 Downregulates Inflammatory Mediators and Pathogenic Processes in PBMC From DMARDs-Naïve Rheumatoid Arthritis Patients.
Journal: Frontiers in pharmacology
Published: October 22, 2021
SOX4 and RELA Function as Transcriptional Partners to Regulate the Expression of TNF- Responsive Genes in Fibroblast-Like Synoviocytes.
Journal: Frontiers in immunology
Published: October 04, 2021
Downregulation of Inflammatory Cytokine Release from IL-1β and LPS-Stimulated PBMC Orchestrated by ST2825, a MyD88 Dimerisation Inhibitor.
Journal: Molecules (Basel, Switzerland)
Published: August 17, 2020
Chronic exposure to TNF reprograms cell signaling pathways in fibroblast-like synoviocytes by establishing long-term inflammatory memory.
Journal: Scientific reports
Published: June 26, 2020
PTPN22 +788 G>A (R263Q) Polymorphism is Associated with mRNA Expression but it is not a Susceptibility Marker for Rheumatoid Arthritis Patients from Western Mexico.
Journal: Biochemical genetics
Published: August 09, 2018
Association of 86 bp variable number of tandem repeat (VNTR) polymorphism of interleukin-1 receptor antagonist (IL1RN) with susceptibility and clinical activity in rheumatoid arthritis.
Journal: Clinical rheumatology
Published: January 13, 2017
Showing 1-12 of 12
Last Updated: 09/26/2026